KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Assets (2017 - 2025)

Aquestive Therapeutics has reported Assets over the past 9 years, most recently at $160.4 million for Q4 2025.

  • Quarterly results put Assets at $160.4 million for Q4 2025, up 58.17% from a year ago — trailing twelve months through Dec 2025 was $160.4 million (up 58.17% YoY), and the annual figure for FY2025 was $160.4 million, up 58.17%.
  • Assets for Q4 2025 was $160.4 million at Aquestive Therapeutics, down from $163.6 million in the prior quarter.
  • Over the last five years, Assets for AQST hit a ceiling of $163.6 million in Q3 2025 and a floor of $51.8 million in Q3 2022.
  • Median Assets over the past 5 years was $63.6 million (2021), compared with a mean of $84.6 million.
  • Biggest five-year swings in Assets: soared 111.35% in 2024 and later fell 21.07% in 2025.
  • Aquestive Therapeutics' Assets stood at $62.0 million in 2021, then fell by 7.94% to $57.1 million in 2022, then rose by 0.61% to $57.4 million in 2023, then skyrocketed by 76.64% to $101.4 million in 2024, then skyrocketed by 58.17% to $160.4 million in 2025.
  • The last three reported values for Assets were $160.4 million (Q4 2025), $163.6 million (Q3 2025), and $93.7 million (Q2 2025) per Business Quant data.